in managing cancer metastasis is significant. However, low CTC isolation purities from patient blood have hindered sensitive molecular assays of these rare cells. Described herein is the ultra-pure isolation of CTCs from patient blood samples and how this platform has enabled highly specific molecular (mRNA and miRNA) profiling of patient CTCs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039969 | PMC |
http://dx.doi.org/10.1002/advs.201600063 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!